Last reviewed · How we verify
TP-03, 0.25%
At a glance
| Generic name | TP-03, 0.25% |
|---|---|
| Also known as | Lotilaner ophthalmic solution, 0.25% |
| Sponsor | Tarsus Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD (PHASE2)
- A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects (PHASE1)
- Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex (PHASE2)
- Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (PHASE2, PHASE3)
- Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TP-03, 0.25% CI brief — competitive landscape report
- TP-03, 0.25% updates RSS · CI watch RSS
- Tarsus Pharmaceuticals, Inc. portfolio CI